DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Martinez-Useros J, Rodriguez-Remirez M, Borrero-Palacios A, Moreno I, Cebrian A, Gomez del Pulgar T, del Puerto-Nevado L, Vega-Bravo R, Puime-Otin A, Perez N, Zazo S, Senin C, Fernandez-Aceñero MJ, Soengas MS, Rojo F, Garcia-Foncillas J.
Martinez-Useros J, et al. Among authors: cebrian a.
BMC Cancer. 2014 Dec 16;14:965. doi: 10.1186/1471-2407-14-965.
BMC Cancer. 2014.
PMID: 25515240
Free PMC article.